Tubercular involvement of pancreas is rare. It presents as a focal lesion of pancreas on cross sectional imaging. Endosonography with fine-needle aspiration (EUS-FNA) is important for a effectively timed presurgical evaluation.
A retrospective evaluation was carried out on 117 circumstances of pancreatic focal mass current course of EUS-FNA at our institution over a interval of three years, and 5 circumstances with pancreatic tuberculosis (TB) had been detected.
The medical presentation numerous from obstructive jaundice, recurrent acute pancreatitis to incidentaloma of pancreas. All victims acquired antitubercular treatment and had been adopted up for on the very least 6 months.
In conclusion, pancreatic tuberculosis is a differential of a pancreatic focal lesion and EUS-FNA is the technique for evaluation of this case that can obviate surgical exploration.
Mycobacterium tuberculosis-Explicit T Cell Purposeful, Memory, and Activation Profiles in QuantiFERON-Reverters Are Fixed With Managed An infectioN
Reversion of immune sensitization exams for Mycobacterium tuberculosis (M.tb) an an infection, resembling interferon-gamma launch assays or tuberculin pores and pores and skin test, has been reported in quite a few analysis.
We hypothesized that QuantiFERON-TB Gold (QFT) reversion is said to a decline of M.tb-specific helpful T cell responses, and a particular pattern of T cell and innate responses as compared with persistent QFT+ and QFT- individuals.
We in distinction groups of healthful adolescents (n=~30 each), outlined by 4, 6-monthly QFT exams: reverters (QFT+/+/-/-), non-converters (QFT-/-/-/-) and persistent positives (QFT+/+/+/+).
We stimulated peripheral blood mononuclear cells with M.tb antigens (M.tb lysate; CFP-10/ESAT-6 and EspC/EspF/Rv2348 peptide swimming swimming pools) and measured M.tb-specific adaptive T cell memory, activation, and helpful profiles; along with helpful innate (monocytes, pure killer cells), donor-unrestricted T cells (DURT: γδ T cells, mucosal-associated invariant T and pure killer T-like cells) and B cells by motion cytometry.
Projection to latent home discriminant analysis was utilized to seek out out choices that most interesting distinguished between QFT reverters, non-converters and persistent positives. No longitudinal modifications in immune responses to M.tb had been seen upon QFT reversion.
M.tb-specific Th1 responses detected in reverters had been of intermediate magnitude, bigger than responses in QFT non-converters and reduce than responses in persistent positives.
About one third of reverters had a robust response to CFP-10/ESAT-6. Amongst these with measurable responses, lower proportions of TSCM (CD45RA+CCR7+CD27+) and early differentiated (CD45RA-) IFN-γ-TNF+IL-2- M.tb lysate-specific CD4+ cells had been seen in reverters in distinction with non-converters.
Conversely, bigger proportions of early differentiated and reduce proportions of effector (CD45RA-CCR7-) CFP10/ESAT6-specific Th1 cells had been seen in reverters as compared with persistent-positives. No variations in M.tb-specific innate, DURT or B cell helpful responses had been seen between the groups.
Statistical modelling misclassified the overwhelming majority of reverters as non-converters additional usually than that they had been appropriately categorised as reverters or misclassified as persistent positives.
These findings suggest that QFT reversion occurs in a heterogeneous group of individuals with low M.tb-specific T cell responses. In some individuals QFT reversion may finish end result from assay variability, whereas in others the magnitude and differentiation standing of M.tb-specific Th1 cells are in line with well-controlled M.tb an an infection.
Disseminated Tuberculosis Associated With Adalimumab Treatment
Therapeutic blockade of tumour necrosis difficulty alpha (anti-TNF-α) is the mainstay remedy of quite a few rheumatologic sicknesses. They’re unfrequently associated to opportunistic infections and latent tuberculosis (TB) screening is paramount sooner than immunosuppression.
A 62-year-old man with psoriatic arthritis was beneath remedy with adalimumab for over 5 years. The screening for latent tuberculosis an an infection (LTBI) earlier to the start of immunosuppression was detrimental, and a subsequent interferon gamma launch assay 4 years later was moreover detrimental.
He launched inside the emergency division complaining of asthenia, anorexia, fever, night sweats and weight discount for over 5 months. He moreover complained of memory loss, no matter his common cognitive and neurological examination.
After an exhaustive workup, he was recognized with a disseminated tuberculosis (cerebral, pulmonary and peritoneal) and dealt with accordingly. TB evaluation stays troublesome in positive situations.
Latent TB screening exams may lack sensitivity and immunosuppressive treatment will improve the hazard of disseminated an an infection. We discuss in regards to the workup and administration of a central nervous system disseminated TB related to adalimumab treatment.
Distinction-Enhanced Ultrasound Imaging Choices of Focal Splenic Tuberculosis
BACKGROUND The aim of this look at was to characterize the contrast-enhanced ultrasound imaging choices of focal splenic tuberculosis. MATERIAL AND METHODS We retrospectively analyzed the usual ultrasound (US) and contrast-enhanced ultrasound (CEUS) imaging choices of 22 victims with splenic TB confirmed by surgical histopathology or biopsy.
RESULTS Typical US demonstrated that 15 of the 22 victims had a single lesion, whereas 7 had quite a few lesions. The utmost diameter of the lesions ranged from 1.zero to a few.7 cm. Of the 22, 17 had been detected with hypoecho and 5 had been detected with superior echo by typical US. Seven (7/22) had been detected with blood motion alerts by coloration Doppler motion image (CDFI).
CUES demonstrated that 18 circumstances (81.8%, 18/22) began to bolster inside the arterial part, principally adopted by gradual wash-out inside the intermediate or late parenchymal part, and 4 (18.2%, 4/22) launched with non-enhancement all through all phases.
The enhancement patterns had been categorized into 4 kinds: Variety I, homogeneous enhancement (2/22); Variety II, rim-like enhancement (12/22); Variety III, septation-like enhancement (4/22); and Variety IV, non-enhancement (4/22).
CONCLUSIONS CEUS confirmed that splenic TB lesions had been enhanced inside the arterial part, adopted by gradual washed out or persistent enhancement inside the intermediate and late parenchymal phases.
The rim- or septation-like enhancement may be helpful for diagnosing splenic TB. The splenic lesions presenting spherical hypoecho by typical US and full non-enhancement by CEUS are extraordinarily suspicious of splenic TB.
A high-frequency single nucleotide polymorphism inside the MtrB sensor kinase in medical strains of Mycobacterium tuberculosis alters its biochemical and physiological properties
The DNA polymorphisms current in medical strains of Mycobacterium tuberculosis drive altered physiology, virulence, and pathogenesis in them.
Although the lineages of these medical strains might be traced once more to frequent ancestor/s, there exists a plethora of distinction between them, in distinction to individuals who have developed inside the laboratory.
We decide a mutation present in ~80% of medical strains, which maps inside the HATPase space of the sensor kinase MtrB and alters kinase and phosphatase actions, and impacts its physiological perform.
The modifications conferred by the mutation had been probed by in-vitro biochemical assays which revealed modifications in signaling properties of the sensor kinase. These modifications moreover impact bacterial cell division costs, measurement and membrane properties.
Brucella Abortus Antigen |
NAT41599-500 |
The Native Antigen Company |
0.5 |
EUR 1176.24 |
Description: Brucella abortus lysate, produced by fermentation. |
Candida Albicans Antigen |
NAT41601-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Candida albicans is grown on solid medium, washed, disrupted and subjected to an extraction process. The antigen consists of cytoplasmic and cell wall components. |
Candida Albicans Antigen |
NAT41601-500 |
The Native Antigen Company |
0.5 |
EUR 1176.24 |
Description: Candida albicans is grown on solid medium, washed, disrupted and subjected to an extraction process. The antigen consists of cytoplasmic and cell wall components. |
Canine Parvovirus Antigen |
NAT41594-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Canine Parvovirus, produced in CRFK cells. |
Canine Coronavirus Antigen |
NAT41590-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Canine Coronavirus produced in A-72 cells. |
Feline Calicivirus Antigen |
NAT41595-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Feline Calicivirus produced in FC 3TG cells. |
Helicobacter Pylori Antigen |
NAT41603-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Bacteria are cultured on solid medium, harvested, washed and solubilised. The antigen is partially purified by detergent extraction and centrifugation. |
Helicobacter Pylori Antigen |
NAT41603-500 |
The Native Antigen Company |
0.5 |
EUR 1176.24 |
Description: Bacteria are cultured on solid medium, harvested, washed and solubilised. The antigen is partially purified by detergent extraction and centrifugation. |
Campylobacter Jejuni Antigen |
NAT41600-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Campylobacter jejuni is cultured on solid medium. This antigen is a partially purified detergent extract of the membrane fraction. The main component is an outer membrane protein, approximately 45 kDa in SDS-PAGE. |
Campylobacter Jejuni Antigen |
NAT41600-500 |
The Native Antigen Company |
0.5 |
EUR 1176.24 |
Description: Campylobacter jejuni is cultured on solid medium. This antigen is a partially purified detergent extract of the membrane fraction. The main component is an outer membrane protein, approximately 45 kDa in SDS-PAGE. |
mycobacterium tuberculosis Antigen 85A Recombinant Protein |
PROTP9WQP3 |
BosterBio |
10ug |
EUR 265 |
Description: mycobacterium tuberculosis Antigen 85A Recombinant Protein expressed in Baculovirus with His-tag. Sequence domain: 44-338aa. Application(s): SDS-PAGE. Endotoxin: < 1 EU per 1ug of protein (determined by LAL method). |
Chlamydia Trachomatis Antigen |
CT022-1000 |
The Native Antigen Company |
1.0 |
EUR 378.9 |
Description: Chlamydia trachomatis antigens from clarified cell lysate. |
Neisseria Gonorrhoeae Antigen |
NG01-1000 |
The Native Antigen Company |
1.0 |
EUR 378.9 |
Description: Homogenised lysate of pure bacteria. |
Mycoplasma Pneumoniae Antigen |
MP901-1000 |
The Native Antigen Company |
1.0 |
EUR 1010.39 |
Description: Mycoplasma pneumoniae whole organisms that have been purified and detergent treated to enrich antigenic proteins and decrease background. |
Mycoplasma Pneumoniae Antigen |
MP901-200 |
The Native Antigen Company |
0.2 |
EUR 270.46 |
Description: Mycoplasma pneumoniae whole organisms that have been purified and detergent treated to enrich antigenic proteins and decrease background. |
Echovirus Antigen, Recombinant |
REC31776-100 |
The Native Antigen Company |
0.1 |
EUR 276.84 |
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus |
Echovirus Antigen, Recombinant |
REC31776-500 |
The Native Antigen Company |
0.5 |
EUR 1043.56 |
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus |
Trichomonas Vaginalis Antigen |
TV01-1000 |
The Native Antigen Company |
1.0 |
EUR 421 |
Description: Washed & lysed suspension of whole protozoa |
Echinococcus Granulosus Antigen |
NAT41602-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Echinococcus granulosus material is derived from bovine hydatid cyst as sterile filtered cyst fluid. |
Echinococcus Granulosus Antigen |
NAT41602-500 |
The Native Antigen Company |
0.5 |
EUR 1176.24 |
Description: Echinococcus granulosus material is derived from bovine hydatid cyst as sterile filtered cyst fluid. |
Enterovirus Antigen, Recombinant |
REC31772-100 |
The Native Antigen Company |
0.1 |
EUR 276.84 |
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus IgA, IgG and IgM ELISA. |
Enterovirus Antigen, Recombinant |
REC31772-500 |
The Native Antigen Company |
0.5 |
EUR 1043.56 |
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus IgA, IgG and IgM ELISA. |
Cytomegalovirus Purified Antigen |
CMV-HP-100 |
The Native Antigen Company |
0.1 |
EUR 318.94 |
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
Cytomegalovirus Purified Antigen |
CMV-HP-1000 |
The Native Antigen Company |
1.0 |
EUR 2096.06 |
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
Cytomegalovirus Purified Antigen |
CMV-HP-500 |
The Native Antigen Company |
0.5 |
EUR 1279.58 |
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
Astrovirus Antigen (Type 1) |
AS02-1000 |
The Native Antigen Company |
1.0 |
EUR 1654.65 |
Description: A concentrated source of Astrovirus particles and Astrovirus proteins from a lysate of host cells. |
Astrovirus Antigen (Type 1) |
AS02-200 |
The Native Antigen Company |
0.2 |
EUR 442.69 |
Description: A concentrated source of Astrovirus particles and Astrovirus proteins from a lysate of host cells. |
Yersinia pestis V antigen |
REC32028-100 |
The Native Antigen Company |
0.1 |
EUR 491.53 |
Description: Yersinia pestis V antigen (LcrV antigen, capsule protein fraction 1, type III secretion system needle tip protein). The protein is produced as an N-terminal GST fusion, with GST being cleaved by thrombin and is not present in the final product. |
Yersinia pestis V antigen |
REC32028-500 |
The Native Antigen Company |
0.5 |
EUR 2421.37 |
Description: Yersinia pestis V antigen (LcrV antigen, capsule protein fraction 1, type III secretion system needle tip protein). The protein is produced as an N-terminal GST fusion, with GST being cleaved by thrombin and is not present in the final product. |
Canine Herpes Virus Antigen |
NAT41592-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Canine Herpes virus, produced in MDCK cells. |
Canine Adenovirus 1 Antigen |
NAT41587-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Canine Adenovirus Type 1, produced in A-72 cells. |
Canine Adenovirus 2 Antigen |
NAT41588-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Canine Adenovirus Type 2, produced in A-72 cells. |
Canine Distemper Virus Antigen |
NAT41591-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Canine Distemper virus, produced in SL-29 cells. |
Canine Parainfluenza Virus Antigen |
NAT41593-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Canine Parainfluenza virus antigen, produced in MDCK cells. |
Feline Panleukopenia Virus Antigen |
NAT41597-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Feline Panleukopenia Virus (FPLV; feline parvovirus) antigen, produced in CRFK cells. |
Norovirus GII.4 VP1 Antigen |
REC31620-100 |
The Native Antigen Company |
0.1 |
EUR 302.36 |
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
Norovirus GII.4 VP1 Antigen |
REC31620-1000 |
The Native Antigen Company |
1.0 |
EUR 1830.71 |
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
Norovirus GII.4 VP1 Antigen |
REC31620-500 |
The Native Antigen Company |
0.5 |
EUR 1066.53 |
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
Cytomegalovirus Cell Lysate Antigen |
CMV-CL-100 |
The Native Antigen Company |
0.1 |
EUR 223.26 |
Description: A clarified cell lysate containing a mix of CMV antigens from all stages of the replication life cycle. |
Cytomegalovirus Cell Lysate Antigen |
CMV-CL-1000 |
The Native Antigen Company |
1.0 |
EUR 1422.47 |
Description: A clarified cell lysate containing a mix of CMV antigens from all stages of the replication life cycle. |
Feline Viral Rhinotracheitis Antigen |
NAT41598-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Feline Viral Rhinotracheitis (FVR; feline herpes virus, FHV-1) antigen, produced in CRFK cells. |
Herpes Simplex Virus 1 Antigen |
HS105-1000 |
The Native Antigen Company |
1.0 |
EUR 1178.79 |
Description: HSV-1 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
Herpes Simplex Virus 1 Antigen |
HS105-200 |
The Native Antigen Company |
0.2 |
EUR 294.7 |
Description: HSV-1 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
Herpes Simplex Virus 2 Antigen |
HS205-1000 |
The Native Antigen Company |
1.0 |
EUR 1178.79 |
Description: HSV-2 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
Herpes Simplex Virus 2 Antigen |
HS205-200 |
The Native Antigen Company |
0.2 |
EUR 294.7 |
Description: HSV-2 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
Ross River Virus Recombinant Antigen |
REC31969-100 |
The Native Antigen Company |
0.1 |
EUR 757.8 |
Description: Recombinant Ross River virus antigen expressed in HEK293 cells as virus-like particles and purified by sucrose density gradients and precipitation. Virus-like particles were then solubilized in PBS containing 0.2% SDS to prevent aggregation of particles. The preparation is not particulate. Antigens in the preparation include Envelope proteins 1 and 2 and Nucleoprotein. |
Ross River Virus Recombinant Antigen |
REC31969-500 |
The Native Antigen Company |
0.5 |
EUR 2844.92 |
Description: Recombinant Ross River virus antigen expressed in HEK293 cells as virus-like particles and purified by sucrose density gradients and precipitation. Virus-like particles were then solubilized in PBS containing 0.2% SDS to prevent aggregation of particles. The preparation is not particulate. Antigens in the preparation include Envelope proteins 1 and 2 and Nucleoprotein. |
Canine Adenovirus 1 and 2 Antigen |
NAT41589-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: A mixture of Canine Adenovirus Type 1 and Type 2, produced in A-72 cells. |
Hepatitis B Virus E Antigen (HBeAg) |
REC31677-100 |
The Native Antigen Company |
0.1 |
EUR 456.72 |
Description: Recombinant Hepititis B Virus E Protein (HBeAg). |
Hepatitis B Virus E Antigen (HBeAg) |
REC31677-500 |
The Native Antigen Company |
0.5 |
EUR 1941.06 |
Description: Recombinant Hepititis B Virus E Protein (HBeAg). |
Hepatitis B Virus Core Antigen (HBcAg) |
REC31689-100 |
The Native Antigen Company |
0.1 |
EUR 456.72 |
Description: Recombinant Hepititis B Virus Core Protein (HBcAg). |
Hepatitis B Virus Core Antigen (HBcAg) |
REC31689-500 |
The Native Antigen Company |
0.5 |
EUR 1370.16 |
Description: Recombinant Hepititis B Virus Core Protein (HBcAg). |
Hepatitis C Virus Core Antigen (HCcAg) |
REC31693-100 |
The Native Antigen Company |
0.1 |
EUR 484.79 |
Description: Recombinant Hepatitis C Virus core protein is produced in E. coli and fused with a His-tag. |
Hepatitis C Virus Core Antigen (HCcAg) |
REC31693-500 |
The Native Antigen Company |
0.5 |
EUR 1455.64 |
Description: Recombinant Hepatitis C Virus core protein is produced in E. coli and fused with a His-tag. |
Feline Infectious Peritonitis Virus Antigen |
NAT41596-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Feline Infectious Peritonitis virus (FIPV; feline coronavirus) antigen, produced in CRFK cells. |
Herpes Simplex Virus 1 Lysate Antigen |
HS104-1000 |
The Native Antigen Company |
1.0 |
EUR 270.46 |
Description: A high concentration of HSV-1 particles and proteins from a clarified cell lysate. |
Herpes Simplex Virus 2 Lysate Antigen |
HS204-1000 |
The Native Antigen Company |
1.0 |
EUR 270.46 |
Description: A high concentration of HSV-2 particles and proteins from a clarified cell lysate. |
Legionella pneumophila antigen (native extract) |
NAT41580-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Inactivated Legionella pneumophila antigen from culture. |
Streptococcus Pneumoniae Antigen, Native Extract |
NAT41604-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Inactivated Streptococcus pneumoniae antigen from culture. |
Leptospira Biflexa Antigen (Strain Patoc 1) |
NAT41582-100 |
The Native Antigen Company |
0.1 |
EUR 391.66 |
Description: Inactivated Leptospira biflexa antigen (Strain Patoc 1) from broth culture. |
Leptospira Biflexa Antigen (Strain Patoc 1) |
NAT41582-500 |
The Native Antigen Company |
0.5 |
EUR 1176.24 |
Description: Inactivated Leptospira biflexa antigen (Strain Patoc 1) from broth culture. |
Antigen 85A, 43-338aa, Mycobacterium tuberculosis, His tag, Baculovirus |
MBS204142-001mg |
MyBiosource |
0.01mg |
EUR 230 |
Antigen 85A, 43-338aa, Mycobacterium tuberculosis, His tag, Baculovirus |
MBS204142-005mg |
MyBiosource |
0.05mg |
EUR 405 |
Antigen 85A, 43-338aa, Mycobacterium tuberculosis, His tag, Baculovirus |
MBS204142-025mg |
MyBiosource |
0.25mg |
EUR 985 |
Antigen 85A, 43-338aa, Mycobacterium tuberculosis, His tag, Baculovirus |
MBS204142-5x025mg |
MyBiosource |
5x0.25mg |
EUR 4180 |
Mouse Anti-Hepatitis B Surface Antigen Antibody (1834) |
MAB12230-100 |
The Native Antigen Company |
0.1 |
EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus surface antigen (1834). |
Mouse Anti-Hepatitis B Surface Antigen Antibody (1837) |
MAB12231-100 |
The Native Antigen Company |
0.1 |
EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus surface antigen (1837) |
Mouse Anti-Hepatitis B Surface Antigen Antibody (1838) |
MAB12232-100 |
The Native Antigen Company |
0.1 |
EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus surface antigen (1838) |
Mouse Anti-Hepatitis B Virus E Antigen Antibody (1892) |
MAB12226-100 |
The Native Antigen Company |
0.1 |
EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1892) |
Mouse Anti-Hepatitis B Virus E Antigen Antibody (1893) |
MAB12227-100 |
The Native Antigen Company |
0.1 |
EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1893) |
Mouse Anti-Hepatitis B Virus E Antigen Antibody (1894) |
MAB12228-100 |
The Native Antigen Company |
0.1 |
EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1894) |
Mycobacterium Tuberculosis major secretory protein Antigen 85A Protein |
20-abx262511 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
Mycobacterium Tuberculosis major secretory protein Antigen 85A Protein |
abx262511-10mg |
Abbexa |
10 mg |
EUR 325 |
Mycobacterium Tuberculosis major secretory protein Antigen 85A Protein |
abx262511-25mg |
Abbexa |
25 mg |
EUR 6575 |
Mycobacterium Tuberculosis major secretory protein Antigen 85A Protein |
abx262511-5mg |
Abbexa |
5 mg |
EUR 225 |
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M132) |
MAB12298-100 |
The Native Antigen Company |
0.1 |
EUR 276.84 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M132) |
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M132) |
MAB12298-500 |
The Native Antigen Company |
0.5 |
EUR 695.29 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M132) |
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M133) |
MAB12299-100 |
The Native Antigen Company |
0.1 |
EUR 276.84 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M133) |
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M133) |
MAB12299-500 |
The Native Antigen Company |
0.5 |
EUR 695.29 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M133) |
Mycobacterium Tuberculosis major secretory protein Antigen 85A Recombinant |
rAP-3658 |
Angio Proteomie |
Inquiry |
Ask for price |
Recombinant Mycobacterium Tuberculosis major secretory protein Antigen 85A |
MBS144787-0002mg |
MyBiosource |
0.002mg |
EUR 240 |
Recombinant Mycobacterium Tuberculosis major secretory protein Antigen 85A |
MBS144787-001mg |
MyBiosource |
0.01mg |
EUR 310 |
Recombinant Mycobacterium Tuberculosis major secretory protein Antigen 85A |
MBS144787-1mg |
MyBiosource |
1mg |
EUR 5345 |
Recombinant Mycobacterium Tuberculosis major secretory protein Antigen 85A |
MBS144787-5x1mg |
MyBiosource |
5x1mg |
EUR 23725 |
Yersinia pestis chain B F1 capsule antigen, C-terminal His-tag |
REC32027-100 |
The Native Antigen Company |
0.1 |
EUR 491.53 |
Description: Yersinia pestis chain B F1 capsule antigen (Antig_Caf1) |
Yersinia pestis chain B F1 capsule antigen, C-terminal His-tag |
REC32027-500 |
The Native Antigen Company |
0.5 |
EUR 2421.37 |
Description: Yersinia pestis chain B F1 capsule antigen (Antig_Caf1) |
Ag85A Mycobacterium Tuberculosis major secretory protein Antigen 85A Recombinant Protein |
PROTP0A4V2 |
BosterBio |
Regular: 10ug |
EUR 380.4 |
Description: Recombinant Mycobacterium tuberculosis Ag85A (43-338 a.a) produced in Hi-5 cells is a single, glycosylated polypeptide chain having a molecular mass of 32.8kDa (305 a.a in total).;Antigen 85A is fused to a His tag at C-terminus and purified by conventional chromatographic techniques. |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) |
MBS6006525-02mL |
MyBiosource |
0.2(mL |
EUR 695 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) |
MBS6006525-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2975 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (AP) |
MBS6301005-02mL |
MyBiosource |
0.2mL |
EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (AP) |
MBS6301005-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (PE) |
MBS6301015-02mL |
MyBiosource |
0.2mL |
EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (PE) |
MBS6301015-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (APC) |
MBS6301006-02mL |
MyBiosource |
0.2mL |
EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (APC) |
MBS6301006-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (FITC) |
MBS6301008-02mL |
MyBiosource |
0.2mL |
EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (FITC) |
MBS6301008-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (Biotin) |
MBS6301007-02mL |
MyBiosource |
0.2mL |
EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (Biotin) |
MBS6301007-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
HCV NS3 1359-1456aa antigen |
00154-V-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 |
HCV NS3 1359-1456aa antigen |
00154-V-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 |
HLA Class 1 Antigen A25,A32 |
MBS602885-01mL |
MyBiosource |
0.1mL |
EUR 1290 |
HLA Class 1 Antigen A25,A32 |
MBS602885-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5650 |
HLA Class 1 Antigen A23,A24 |
MBS602995-01mL |
MyBiosource |
0.1mL |
EUR 1380 |
HLA Class 1 Antigen A23,A24 |
MBS602995-5x01mL |
MyBiosource |
5x0.1mL |
EUR 6060 |
A549 HCP Control Antigen |
F237 |
Cygnus Technologies |
50 ul |
EUR 308.4 |
|
Description: A549 HCP Control Antigen by Cygnus Technologies is available in Europe via Gentaur. |
Cancer Antigen 242 Antigen |
VAng-Cr3876-10kU |
Creative Biolabs |
10 kU |
EUR 505.2 |
Description: Cancer Antigen 242 Antigen, Host/Source: Metastatic Liver. The purity is detected by gel filtration. |
HLA Class 1 Antigen A11 |
MBS601315-01mL |
MyBiosource |
0.1mL |
EUR 1380 |
HLA Class 1 Antigen A11 |
MBS601315-5x01mL |
MyBiosource |
5x0.1mL |
EUR 6060 |
HLA Class 1 Antigen A29 |
MBS603635-01mL |
MyBiosource |
0.1mL |
EUR 1380 |
HLA Class 1 Antigen A29 |
MBS603635-5x01mL |
MyBiosource |
5x0.1mL |
EUR 6060 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 405) |
MBS6301010-01mL |
MyBiosource |
0.1mL |
EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 405) |
MBS6301010-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 490) |
MBS6301011-01mL |
MyBiosource |
0.1mL |
EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 490) |
MBS6301011-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 550) |
MBS6301012-01mL |
MyBiosource |
0.1mL |
EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 550) |
MBS6301012-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 650) |
MBS6301013-01mL |
MyBiosource |
0.1mL |
EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 650) |
MBS6301013-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 750) |
MBS6301014-01mL |
MyBiosource |
0.1mL |
EUR 980 |
GAGE13, NT (GAGE13, GAGE12A, G antigen 13, G antigen 12A) (MaxLight 750) |
MBS6301014-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
Antigen 85-A Antibody (HRP) |
20-abx109227 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
The look at highlights the have an effect on of DNA polymorphisms on the pathophysiology of medical strains and provides insights into underlying mechanisms that drive signal transduction in pathogenic micro organism.